BridgeBio Oncology Therapeutics (BBOT) announced leadership changes effective April 20, 2026:
Chief Scientific Officer Pedro Beltran named CEO, succeeding Eli Wallace who became senior adviser; Idan Elmelech promoted to COO; Neil Kumar appointed Executive Chairman.123
The changes aim to accelerate BBOT's RAS and PI3Kα programs entering Phase 1b expansions, with data updates expected in H2 2026 for BBO-8520, BBO-11818, and BBO-10203.12
BBOT shares declined 18% over the past year to $8.76, with a further 4.6% drop on announcement day, amid stronger performance by RAS competitors like Erasca (+482%) and Revolution Medicines (+77%).12
BBOT originated as a 2024 spinout from BridgeBio Pharma and has a $425.5M cash runway into 2028.2
RAS mutations drive ~30% of cancers; BBOT seeks to advance beyond Amgen's Lumakras (approved 2021).1
Sources:
1. https://www.biospace.com/business/bbot-shakes-up-leadership-as-ras-competitors-get-more-visibility
2. https://www.stocktitan.net/news/BBOT/bbot-announces-the-appointment-of-pedro-j-beltran-ph-d-as-chief-u0xk7etsk8qi.html
3. https://www.streetinsider.com/Management+Changes/BBOT+names+Pedro+Beltran+CEO,+Idan+Elmelech+COO+in+leadership+transition/26348265.html